Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New brain wave test could revolutionize hearing loss diagnosis

NCT ID NCT07091071

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new device called CochSyn that measures brain waves to detect hearing damage. Researchers compared results from 65 adults with and without hearing difficulties. The goal was to see if the device can accurately identify different types of hearing loss and be easy to use in clinics.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

65 people

The number who actually took part.

Started

Oct 2025

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 77 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18-77 years (limits included) * Ability to fill out a questionnaire and to perform a speech intelligibility test * Dutch or French as native language • Control group * No self-reported hearing difficulties according to HHIE-s questionnaire (score of ≤4) • Test group * Self-reported hearing difficulties according to HHIE-s questionnaire (score of \>4) • Subgroup DFNA9: * Genetically tested and confirmed to have DFNA9 related hearing loss. Note: This genetic testing was performed through standard of care testing, prior to participation in the study. Exclusion Criteria: * Audiometric hearing loss classifications of Moderate, Moderately severe, Severe, Profound as defined by (Clark, 1981) of the tested ear * Asymmetrical hearing loss Note 1: Asymmetrical hearing loss is defined as an average difference of more than 15dB between both ears across the frequencies of 500, 1000, 2000 and 4000 Hz. The sum of loss in dB is divided by 4 and rounded up. A frequency not perceived is considered a loss of 120 dB. Note 2: This exclusion criterium is not applicable for the DFNA 9 subgroup * Tinnitus with a clinical handicap index (TFI) \> 25. * Patients with type AD, AS, B or C tympanograms * Conductive hearing loss on the tested ear at the discretion of the investigator * Genetic hearing loss of the tested ear Note: This exclusion criterium is not applicable for the DFNA9 subgroup. * Congenital hearing loss of the tested ear Note: This exclusion criterium is not applicable for the DFNA9 subgroup. * Blocked ear canal(s) of the tested ear * Pregnant or breast-feeding * Hearing aid user on the tested ear * Middle ear surgery on the tested ear * Acute ear infection of the tested ear * Acute external auditory canal trauma on the tested ear * Participation in session 2 of previous clinical trial NCT06114680

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cochlear hearing loss are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CHU de Liège

    Liège, Belgium

  • University Hospital Antwerp (UZA)

    Antwerp, Belgium

  • University Hospital Ghent

    Ghent, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.